IP Verse

Dry Powder Formulations Comprising Vilanterol - EP2957551

The patent EP2957551 was granted to Arven Ilac Sanayi VE Ticaret on Jan 15, 2020. The application was originally filed on Jun 15, 2015 under application number EP15172079A. The patent is currently recorded with a legal status of "Revoked".

EP2957551

ARVEN ILAC SANAYI VE TICARET
Application Number
EP15172079A
Filing Date
Jun 15, 2015
Status
Revoked
Jun 24, 2022
Grant Date
Jan 15, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

VECTURAOct 14, 2020CLARKEADMISSIBLE
LEDERER & KELLER PATENTANWALTE PARTNERSCHAFT MBBOct 13, 2020LEDERER & KELLER PATENTANWALTE PARTNERSCHAFT MBBADMISSIBLE
GILL JENNINGS & EVERYOct 12, 2020-ADMISSIBLE
BECK GREENEROct 1, 2020ELKINGTON AND FIFEADMISSIBLE

Patent Citations (11) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONGB2242134
DESCRIPTIONWO03024439
OPPOSITIONWO0053157
OPPOSITIONWO0178693
OPPOSITIONWO0243701
OPPOSITIONWO2010097115
OPPOSITIONWO2011067212
OPPOSITIONWO2012028663
OPPOSITIONWO2014155134
OPPOSITIONWO2015004243
SEARCHWO2010097115

Non-Patent Literature (NPL) Citations (12) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- anonymous, "Basic Principles-Particle-Size-Analysis", Malvern Application Note, (20140000), URL: https://www.atascientific.com.au/wp-content/uploads/2017/02/AN020710-Basic-Principles-Particle-Size-Analysis.pdf, XP055701328-
OPPOSITION- "chapter 5", X.M. ZENG et al., Particulate Interactions in Dry Powder Formulations for Inhalation, (20010000), pages 133 - 173, XP055732888-
OPPOSITION- "Chapter 5", Zeng Ming Xian, Gary P. Martin, Christopher Marriot, Particulate Interactions in Dry Powder Formulations for Inhalation, (20010000), pages 134 - 173, XP055732888-
OPPOSITION- FDA, "BREO ELLIPTA (fluticasone furoate and vilanterol inhalation powder) FOR ORAL INHALATION USE", HIGHLIGHTS OF PRESCRIBING INFORMATION, (20130101), pages 1 - 41, XP055736888-
OPPOSITION- GlaxoSmithKline, "BREO® ELLIPTA™ now available in the U.S. for the treatment of CORD", GSK press release, (20131030), URL: https://www.prnewswire.com/news-releases/breo-ellipta-now-available-in-the-us-for-the-treatment-of-copd-229862421.html, XP055744039-
OPPOSITION- "Particle size analysis by laser diffraction", Anonymous, European Pharmacopoeia 8th EDITION, (20130700), pages 333 - 336, XP055739748-
OPPOSITION- R. MUELLER-WALZ et al., "Ternary additives: manipulation and control with magnesium stearate", R. MUELLER-WALZ et al., Respiratory Drug Deliver, (20060000), pages 343 - 350, XP055514615-
OPPOSITION- ZHOU, Q., "Understanding the influence of powder flowability, fluidization and de-agglomeration characteristics on the aerosolization of pharmaceutical model powders", Eur. J. Pharm. Sc, (20100428), vol. 40, no. 5, pages 412 - 421, XP027093083-
OPPOSITION- R. GUCHARDI et al., "Influence of fine lactose and magnesium stearate on low dose dry powder inhaler formulations", International Journal of Pharmaceutics, (20080000), vol. 348, doi:10.1016/j.ijpharm.2007.06.041, pages 10 - 17, XP022393884
OPPOSITION- Zhou et al., "Effect of mechanical dry particle coating on the improvement of powder flowability for lactose monohydrate: A model cohesive pharmaceutical powder", Powder Technology, (2011), vol. 207, pages 414 - 421, XP055743915
OPPOSITION- C.A. DUNBAR et al., "Dispersion and Characterization of Pharmaceutical Dry Powder Aerosols", KONA, (19980000), vol. 16, pages 7 - 45, XP055460404
OPPOSITION- C.A. DUNBAR et al., "Dispersion and Characterization of Pharmaceutical Dry Powder Aerosols", KONA, (19980000), vol. 16, pages 7 - 54, XP055460404

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents